StreetAlpha.app
Home › Stocks › FLGT

Fulgent Genetics, Inc. (FLGT)

$24.12
▼ −2.66%
LAST CLOSE · NOV 20

Fulgent Genetics provides genetic and diagnostic lab testing for healthcare providers and patients, and develops cancer drug candidates. It last closed at $24.12 on Nov 20, down 2.66% on the day. The next earnings report for FLGT is expected around Fri, Feb 26, 2027. Over its last 8 reports the stock moved an average of 17.1% the session after earnings. Over the last 12 months FLGT insiders bought $0 of stock on the open market and sold $387K, according to SEC Form 4 filings.

AI Auto Pilots
Is FLGT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold FLGT.

Key Stats

Last 12 months
Results
Revenue
$330.3M
+4.7% vs a year ago
Net income
−$90.9M
−27.5% margin
Free cash flow
−$1.4M
−0.4% margin
Gross margin
33.8%
$111.7M gross profit
Valuation
Market cap
$673.9M
27.9M shares
P/E
–
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$86.8M
At Sep 30
Debt
$1.5M
At Sep 30
Shareholder equity
$990.5M
Buybacks
$64.1M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $992.6M$992.6MFY2021FY2022: $619.0M$619.0MFY2022FY2023: $289.2M$289.2MFY2023FY2024: $283.5M$283.5MFY2024FY2025: $322.7M$322.7MFY2025

From FLGT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 26
Estimated date · Time not announced
Reported EPS
—
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
$90.4M
+7.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Dec 2024: $76.2MDec '24Mar 2025: $73.5MMar '25Jun 2025: $81.8MJun '25Sep 2025: $84.1MSep '25Dec 2025: $83.3MDec '25Mar 2026: $71.1MMar '26Jun 2026: $85.4MJun '26Sep 2026: $90.4MSep '26Latest $90.4M
How FLGT moved after its last 8 reports
Average move the session after a report ±17.1%
Nov 5, 2026After the close+27.2%
Jul 30, 2026After the close−18.1%
May 1, 2026Time not announced−7.0%
Feb 27, 2026Time not announced−38.1%
Nov 7, 2025Time not announced+18.1%
Aug 1, 2025Time not announced+7.9%
May 2, 2025Time not announced+19.1%
Feb 28, 2025Time not announced−1.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on FLGTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on FLGT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on FLGT

Technical Analysis

FLGT · as of the Nov 20 close · updated each morning
Uptrend

The stock is 6% above its 20 day and 10% above its 50 day average. It is 21% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 57). The nearest support is the Pivot S1 at $23.74, and the nearest resistance the Pivot at $24.26.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 5.2%/day
Key levels
$31.0452 week high+28.7%
$27.41Swing high (Nov 10)+13.6%
$24.65Pivot R1+2.2%
$24.26Pivot+0.6%
$24.12Last close
$23.74Pivot S1−1.6%
$23.39Swing low (Nov 17)−3.0%
$22.7520 day average−5.7%
$21.8250 day average−9.5%
$20.74100 day average−14.0%
$19.11200 day average−20.8%
$13.4652 week low−44.2%
Indicators
RSI (14)56.87Middle of its rangeNeutral
MACD1.05Above its signal lineBullish
Stochastic69.5Middle of its rangeNeutral
ADX (14)25.2Trending up
Williams %R-36.7Oversold below −80, overbought above −20Neutral
CCI (20)46.2Oversold below −100, overbought above 100Neutral
Rate of change+1.6%Change over 10 sessionsBullish
ATR (14)$1.24Typical daily range, 5.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for FLGT

What happened before

See how FLGT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow FLGT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How FLGT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for FLGTHow many large options trades hit FLGT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

FLGT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●63 buying vs 62 selling
  • ▼Held by funds -1.7 pts
  • ●Funds holding +0
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1421420.0%
In funds' top 10220.0%
Held by funds54.4%56.1%−1.7 pts
New / increased16 / 4720 / 40+5.0%
Reduced / sold out45 / 1755 / 37−32.6%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See FLGT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

FLGT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$387K14 sales · 2 insiders
2025-12 sold $63K2026-05 sold $38K2026-06 sold $69K2026-08 sold $42K2026-09 sold $75KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 2Hanlin GaoChief Scientific OfficerSale1,673$19.66$33K
Sep 2Jian XiePresident and COOSale2,127$19.66$42K
Aug 27Hanlin GaoChief Scientific OfficerSale939$19.91$19K
Aug 27Jian XiePresident and COOSale1,193$19.91$24K
Jun 2Hanlin GaoChief Scientific OfficerSale1,688$17.89$30K
Jun 2Jian XiePresident and COOSale2,146$17.89$38K
Every insider buy and sale for FLGT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See FLGT insider trades →

From SEC Form 4 filings by FLGT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FLGT is in one of them and how their past FLGT trades turned out.

FLGT in the AI portfolios
Loading…

FLGT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered FLGT in an article yet. Here's the latest on the wider market.

FLGT in the news

About Fulgent Genetics

Fulgent Genetics is a laboratory services company based in El Monte, California. It offers genetic testing, diagnostic testing, anatomic pathology services, and physician interpretation of lab results. Its customers include insurers, hospitals, medical institutions, pharmaceutical and biotech companies, and patients who pay directly for tests. The company is also developing cancer drug candidates that use a nanoencapsulation platform.

Headquarters
El Monte, CA
Founded
2011